Evogene Ltd. — Investor Presentation 2023

May 18, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2023

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant 's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Evogene Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: May 18, 2023 By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

Exhibit 99.1

Forward Looking Statement

This presentation contains "forvard-looking to future events, and Evocene Ltd. (the "Company"), may from time nake other statements. reqarding our outlook or expectations for operating results and/or other matters regarding or affecting us that are considered "forward-boking statements" as defined in the U.S. Private Securites Library and other securites laws, as amended. Statements that are not statements of historical fact may be deements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "stimated", "intend" and "potential" or vords of sinilar meaning. We are using forward-looking statenents in this presentation when we discuss our value drining, product development and launches, estimated market sizes and miestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertaintes which are difficult to predict and are of future performance. Readers are cautioned that certain inportant factors nay affect the Company's actual results and could cause such rem any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or acheve in the future may differ materially from what is expessed or implied by such forward-loking statements due to a variety of factors, many of whiching, without limitation, those described in greater detail in Evogene's Annua Report on Form 20-F and in other information Evogene files to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities we digation or commitment to update any information contained in this presentation or to publicy release the results of any revisions to any be made to reflect future events or changes in expectations, estinates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or offer to sell, or any solicitation of any invitation or offer to purchas of Evogene or the Company, nor shall the information or any part of the fact of its distribution for the basis of, or be relied on inch, any action, contract, commitment or relaing thereto or to the securities of Evolene or the Company.

The trademarks included herein are the property of the owners only. Such use should not be construed as an endorsement of our products or services.

evogene

Agenda

* About Evogene

Business model Product-oriented subsidiaries

Summary

Annex I - Financial Fundamentals

OUR VISION

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

evøgene

DECODING BIOLOGY

Life-science product development

Low probability of success with high cost and long time-to-market

Pharma Industry

Cost of developing a single pharmaceutical drug

In the 1970's \$180 million In recent years >\$2 billion Ag-chemicals Industry

Years to develop a new crop protection product

11995	2000		2005-8 2010-15
8	0	10	11+

"https://www.fores.com/since/netherer/2017/0//6/the-as-of-deleavis-insme-apper-that-argued-otherwiss-was-insmely-bad/?sh-7533a82459; Philips Mough, 2016.

Life-science product development The ultimate case of finding "the needle in the haystack"

The challenge: Finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach successful products

evolgene

The opportunity

Utilizing an advanced computational biology platform

To identify the most promising candidates addressing multiple development challenges towards successful life-science products

• · Increase probability of success
• · Reduce time and cost

Biology meets disruptive technologies

Incorporates deep scientific understanding together with big data and advanced AI technologies, to successfully discover & guide the development of novel life-science based products.

evolgene

Tailor-made Tech Engines

The CPB platform enhances product discovery and development through dedicated Technology Engines for products based on three core components:

• · Microbes
• · Small molecules
• · Genetic elements

evogene

Tech Engines accelerating product discovery & development

+ Discovery

Computational selection of the most promising candidates to initiate the product development process.

+ Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to successful commercialization.

evogene

Example of Tech Engine User-enabled software dashboard

Discovery	Di Dataset generation	Oz Function prediction	Bacteria prodiction	(04) Mining and selection	OS Repulation & Palantability	Os Experimental validation	(07) Experiences data analysis
(1)	Generale Bilgitionnesse sua	(a) Collic	Function to Organism (FDO) (0)	Explore Backerla (2) transparties a sports	D APHIS complance	A) (Experiment design	Fungi expedinents
(9)	Download sublic genories	Function 0 exploration apps. Explore	Boreck USE (0) Tradition (ML)	Explore F20 (છે) cesults	B) Shis	(8) Fungi experiments	Phytium pideline A aclaysia
(0)	Canarata Productions	Clustel,EireCOG.KEG G.BLASTEVECOG phenotype		Function (ව) exploration apps	(D) Patercability	Phytium pipeline anlaysia (6)	leaersicide plant (4) ALLAJA 2
				Strain exploisSon (ਨੂ 4000		Insecticide plant (�) assays
				(A) Strain bearing		(Black) Distripo)
46,237 Viz Integrated bacterial genomes 200,599,577 は Probains in our ortholog database	ప్రస్త్ర వై	6,650,502 Ortholog groups in function Carababe 93,995 Ortholog-phenotype associations	CHECK NOW	Check the new app for EvoCOGs association with phenotypes Explore your bacteria for EvoCOGs linked to a specific phenotype, retrieve EvoCOGs linked to specific phenotypes or retrieve bacterial genomes with EvoCOGs linked to specific phenotypes.

evøgene

Building an 'Ecosystem around our tech engines

evøgene

Annex I - Financial Fundamentals

Evogene's Tech Engines - Potential Addressable Markets

evogene

Product-oriented subsidiaries powered by Evogene's technology

Establish independent entities focusing on a defined commercial field with a license to use Evogene's unique solutions for product development

Subsidiaries:

Licensed to use Evogene's tech engines:

Collaborations powered by Evogene's technology for the development of innovative products

Joint development with leading companies for defined products utilizing Evogene's unique solution. Typically, partner leads later-stage development and product commercialization.

Powered by Evogene's tech engines:

evøgene

Evogene's Tech Engines - Current Utilization

evogene

Annex I - Financial Fundamentals

evogene

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology

Products & Pipeline

Immuno-oncology program

• · Combination therapy for cancer with checkpoint inhibitors
• · Phase 1 clinical stage
• · Addressable market of \$309.7B (by 2030*)

GI related disorders

• · Inflammatory Bowel Disorder (IBD) pre-clinical stage
• · Irritable Bowel Syndrome (IBS) discovery stage
• · Addressable market: IBD \$27B; IBS \$3.3B (by 2026**)

Antimicrobial resistance (AMR)

• · Clostridium Difficile Infection (CDI) discovery stage
• · Methicillin-resistant Staphylococcus aureus (MRSA) discovery stage
• · Addressable market: CDI \$1.7B (***); MRSA \$1.3B (by 2026****)

Expected upcoming value drivers

Immuno-oncology

· Readout & completion of POC from first in-human study; Pre-IND meeting with FDA

IBD

· Clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA.

TBS

· Advancement of pre-clinical studies

*https://www.alliedmarketresearch.com/cancer-immunotherapy-market

"https://www.goot.com/ass-eleces-idoratments/short/servations/solor_source/end/im_media=ling.com/gradion_map/sellerse/rectricht/index.prectres/lorier_mail/init_mail.com/ponen http://www.grad.com/index.php?title=149200920091010114149202000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 2026-cagr-10-1-grand-view-research-inc

400 https://www.globaldata.com/media/press-release/qlobal-clostridium-difficile-infections-market-approach-1-7-billion-2026/

*** https://www.biospoce.com/article/releases/global-methiallin-resistant-staphylococas-aureus-market-to-surposs-us-1-3-billion-by-2026/

evogene

Example Results:

Immuno-Oncology program - BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo

Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

evogene

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug JULY 26, 2022

Biomica Announces Closing of \$20 Million Financing Round led by Shanghai Healthcare Capital

APRIL 27, 2023

Mission:

Improve food quality, sustainability & agriculture productivity through microbiome based ag-biologicals technology & products

Products & pipeline (examples)

Bio-stimulants

• · Thrivus™ primarily spring wheat: commercial stage; addressable USA & Canada markets ~25M acres*
• · Bio-stimulants #2 primarily soy: pre-development stage; addressable market ~90M acres*

Bio-pesticides

• · Fruit rots primarily grapes: pre-commercial; addressable market >\$1B**
• Downy Mildew fruits and vegetables; development stage 1; addressable market >\$500M**
• · Seedling disease corn and soy: pre-development; addressable market >\$500M**

Expected upcoming value drivers

Bio-stimulants

· Thrivus™ - distribution licensing agreements and sales expansion in USA & Canada. Expansion to additional crops and an additional territory by 2025

Bio-pesticides:

• · Licensing agreement for Lavie Bio's bio-fungicide candidate for fruit rots (LAV311) - to be finalized during 2023
• · Submission for Lavie Bio's bio-fungicide candidate for downy mildew (LAV321) to the US EPA for regulatory approval - expected by 2024
• · Co-development and licensing agreement for an additional bio-pesticide program with a large multinational company - expected by 2024

"https://www.foo.org/focstaten/#home;https://www.nass.usda.gov.com// https://data.oecd.org/group.top.html ** Company estimation

Thrivus > >

Example Results:

• Thrivus™ inoculant for spring wheat
• LAV 311 bio-fungicide candidates for fruit rot

Lavie Bio's wheat field in the USA during harvest -

Sales initiated in 2022

Example of treatment against Botrytis Cinerea vs untreated control in vines

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement -

Thrivus NOVEMBER 3, 2021

Lavie Bio Reports Successful Results for its Bio-Fungicides Programs

FEBRUARY 28, 2023

evøgene

Powered by

Mission:

Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology

Products & Pipeline

Herbicides

• · Novel Mode-of-Action selective herbicide
• · Herbicides addressable market \$48.9B (2027)*

Fungicides

• · Novel Mode-of-Action wheat blotch fungicide
• · Fungicides addressable market \$25.81B**

Insecticides

• • · Novel Site-of-Action resistance breaking piercing/sucking insecticide
  • · Insecticides addressable market \$22B (2030)***

* https://www.statista.com/statistics/1350387/herbicides-market-size-globally/ ** https://www.fortunebusinessinsights.com/fungiaides-market-103267 *** https://straitsresearch.com/report/insecticides-market

evogene

Expected near-term value drivers

Herbicides

• · Milestone achievement of the ongoing collaboration with Corteva
• · Engage in a new additional strategic collaboration

Fungicides

• · Nominate new Mode-of-Action protein targets
• · Initial greenhouse readouts of designed compounds on the defined fungi targets

Platform

• · Verification of computational tool for selection of novel Mode-of-Action protein targets
• · POC for the computational tool for novel molecule design

Powered by

Example Results:

New MoA Herbicide - APH1

APH1

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

DECEMBER 15, 2020

AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate JULY 6, 2021

evogene

With resistan
trait

Mission:

Provide tailored medical cannabis products to optimize consumer wellbeing.

Products & Pipeline

High Cannabinoid and metabolite content

• · The 'G-nnovation' Series (1st generation)
• 18-19% THC, launched in Oct 2021
• The 'High-bred' Series (2nd generation)
  • 23-24% THC and rich terpene profiles, launched in Oct 2022
  • · Total cannabis market size expected by 2027 \$82.3B*

The 'Precise' Series focus on medical indications

• · Pain management
• · Reduced Inflammation

Expected near-term value drivers

Direct Sales

• · Increased revenues from the 2nd generation products during 2023
• · Launch of 3rd generation products with high THC levels, specific terpene profiles and unique characteristics, towards end of 2023

New revenue streams

• · Commence joint production of Canonic's varieties with a 3rd party based on cost and revenue sharing
• · Royalties from licensing of Canonic's varieties

*https://www.nakesadmarket.com/ltarket-20176801.html#:+:text=The%20gbal%20make%20make%20make%20mm%20dally.

The 'high-bred' series 2nd generation products, examples

Synergy inflorescence

T20/C4 Sativa

Top Characteristics

• · 24% THC
• · High Level of b-Myrcene
• · Genetic Similarity to the Super Lemon Haze' variety

Mash Kush inflorescence

T20/C4 Indica

Top Characteristics

• · 24.4% THC
• · High Level of Terpinolene
• · Genetic Similarity to the `Headband' variety

evolgene

Canonic Successfully Launched Six Second-Generation Cannabis Products with Higher THC and Rich Terpene Profiles

FEBRUARY 21, 2023

Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market MAY 2, 2023

Casteria | Biobased materials

Powered by

Mission:

Leading the castor oil market with an industrialized cultivation of castor in support of the biobased materials industry

Product & Pipeline

Elite castor seed varieties

• · 'FVF' series castor seed suitable for various environmental and climatic conditions
• · Estimated addressable castor oil market \$1.21B (2021) and is expected to expand at CAGR of 5.8% from 2022 to 2030*
• · Main target markets:
  • · Bio-polymers driven by the need for quality and consistent inputs
  • · Bio-fuel driven by environmental & regulatory trends in EU

Agro-technical support

· Cultivation protocols to maximize the results of the elite seeds

Dedicated machinery

• Best-in-class harvesting header, developed with Fantini Srl., Italy

· Casterra proprietary patented dehulling machine

* https://www.grandviewresearch.com/industry-analysis/castor-oil-derivatives-industry

evogene

Expected near-term value drivers

Seeds development

• · Production extending production outreach in the target markets: Africa (Zambia), Latin America (Brazil) with few hundred tons a year as of 2024
• · R&D development of new seed traits matching industry needs (e.g., Ricin free, low viscosity) using advanced technologies: CRISPR, genetic markers

Territorial expansion

• · Africa engaging with bio-fuel strategic industry leaders to increase our sales and sector footprint
• · Latin America addressing the bio-polymer industry's interest in broad, consistent and high-quality castor oil supply in Latin America

Strategic alliance

· A strategic alliance with a leading global biofuel company, leveraging Casterra's holistic industrial solution

Casteria | Biobased materials

High yield & oil castor seeds

Elite castor seed varieties - The 'EVF' series

EVF701

EVF712

EVF716

Dedicated machinery

Castor growth protocol

Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern Africa NOVEMBER 15, 2022

Casterra Announces Agreement with World Leading Energy Company to Cultivate its Castor Varieties at Commercial Scale

JANUARY 19, 2023

evogene

In The News

evogene

Annex I - Financial Fundamentals

Computational systems biology Computational chemistry Bioinformatics Molecular biology Microbiology Genetics Biochemistry

lin

51%

27 %

Incl. chairperson of the board

As of April 30, 2023

evogene

Summary

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies

Strong computational predictive biology (CPB) platform leveraging synergies between a deep understanding of biology, Big Data and AI

Three dedicated Technology Engines for discovery & development:

• · MicroBoost AI for products based on microbes
• · ChemPass AI for products based on small-molecules
• · GeneRator AI for products based on genetic elements

Dual based business model via subsidiaries and collaborations

Market-orientated subsidiaries generating value

• · Biomica Human-microbiome based therapeutics
• Lavie Bio Ag-biologicals
• AgPlenus Ag-chemicals
• · Casterra Castor growth end-to-end solution
• Canonic Medical cannabis

A vote of confidence in Evogene's subsidiaries through equity investment by strategic and financial investors:

Lavie Bio - Corteva & ICL Biomica - SHC

Significant catalysts expected in the coming quarters

evogene

THANK YOU!

Annex I: Financial Fundamentals

evøgene

Key Financials: Balance Sheet

Key Points:

• · Consolidated cash position: ~\$29 million as of 31.03.2023
• · This Consolidated cash position does not include the \$10M Biomica received from the SHC investment in April 2023
• · No bank debt
• · Listed on TASE (2007) and NASDAQ (2016)

Thousands of US \$	31.03.2023	31.12.2022
Current Assets	31,409	37,751
Long-Term Assets	18,066	18,375
Total Assets	49,475	56,126
Current Liabilities	5,356	5,625
Long-Term Liabilities (inc. \$10m convertible SAFE at Lavie Bio)	15,624	15,711
Equity attributable to equity holders of the Company	22,089	27,930
Non-controlling interest	6,406	6,860
Total Liabilities & Shareholders Equity	49,475	56,126

evøgene